Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications.

Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Both characteristics make our vaccine candidates highly desirable.

Out-licensing and different forms of partnering are our preferred offers to companies that are interested in innovative manufacturing and would like to share the success of our Themaxyn® platform.